Quote this publication Share Print

DINUTUXIMAB BETA EUSA (dinutuximab beta), monoclonal antibody

RARE DISEASE - New medicinal product
Opinions on drugs - Posted on Mar 29 2018

Reason for request

Inclusion

Substantial clinical benefit and minor clinical added value in the management of the maintenance phase of high-risk neuroblastoma

but no clinical added value demonstrated in the management of relapsed or refractory neuroblastoma

 

  • DINUTUXIMAB BETA EUSAhas Marketing Authorisation in the treatmentof patients > 12 months of age with high-risk neuroblastoma, who have previously received an induction chemotherapy and had at least a partial response, followed by a myeloablative therapy and a haematopoietic stem cell transplant, as well as in patients with relapsed or refractory neuroblastoma, with or without residual disease.
  • The only comparative study available in the maintenance phase of high-risk neuroblastoma did not demonstrate a benefit from adding an interleukin-2 (IL-2) to the combination of dinutuximab beta and isotretinoin.
  • The efficacy data in the treatment of relapsed or refractory neuroblastoma, with or without residual disease, are of a low level of evidence.
  • The main characteristics of the safety profile are pain, reduced by the use of a continuous perfusion, and capillary leak syndrome.
  • There is insufficient evidence on possible long-term consequences, especially neurological consequences, of treatment with dinutuximab beta for the target population of young children.

 

 


Actual benefit

Important

-


Improvement in actual benefit

IV (mineur)

-

V (absence)


Contact Us

Évaluation des médicaments